Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.42 |
| ▸ | TERT | O14746 | 5/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL9637800 | 0.91 | ERN1 (0.37) | ERN1TERTCCR1TSHRHSD17B10 | |
| SCHEMBL29945725 | 0.87 | ERN1 (0.38) | ERN1TERTCCR1TSHRHSD17B10 | |
| SCHEMBL1572837 | 0.87 | ERN1 (0.38) | ERN1TERTCCR1TSHRHSD17B10 | |
| SCHEMBL23580086 | 0.84 | ERN1 (0.35) | ERN1TERTCCR1HSD17B10S1PR4 | |
| SCHEMBL6551038 | 0.84 | POLB (0.37) | ERN1TERTCCR1CYP1A2CYP3A4 | |
| SCHEMBL30044498 | 0.84 | ERN1 (0.35) | ERN1TERTCCR1HSD17B10S1PR4 | |
| SCHEMBL29237183 | 0.84 | ERN1 (0.38) | ERN1TERTCCR1HSD17B10S1PR4 | |
| SCHEMBL14600867 | 0.79 | ERN1 (0.40) | ERN1TERTTSHRS1PR4TDP1 | |
| SCHEMBL29955993 | 0.78 | CCR1 (0.39) | ERN1TERTCCR1TSHRHSD17B10 | |
| SCHEMBL18243729 | 0.77 | TERT (0.32) | ERN1TERTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235427-A1 | AU(II) DIMERS AND METHODS OF THEIR USE IN CANCER TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9150837-B2 | Polyethylene glycolated superoxide dismutase mimetics | GALERA LABS LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150837-B2 | Polyethylene glycolated superoxide dismutase mimetics | GALERA LABS LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150837-B2 | Polyethylene glycolated superoxide dismutase mimetics | GALERA LABS LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130287696-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | GALERA THERAPEUTICS, LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130287696-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | GALERA THERAPEUTICS, LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130287696-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | GALERA THERAPEUTICS, LLC | 2013-10-31 | — | — | US | disclosed |
| US-20120301403-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | GALERA THERAPEUTICS, LLC (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120301403-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | GALERA THERAPEUTICS, LLC (US) | 2012-11-29 | — | — | US | disclosed |
| US-20040116332-A1 | Biopolymers modified with superoxide dismutase mimics | PHARMACIA CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040110722-A1 | Modified hyaluronic acid polymers | PHARMACIA CORPORATION | 2004-06-10 | — | — | US | disclosed |
| EP-1212323-B1 | SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY | MONSANTO CO (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1420022-A1 | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity | MONSANTO COMPANY (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1420022-A1 | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity | MONSANTO COMPANY (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1420019-A1 | Substituted pyridino pentaazamacrocyle ligands having superoxide dismutase activity | MONSANTO COMPANY (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2001019823-A9 | SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY | MONSANTO CO (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-1212323-A2 | SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY | MONSANTO COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6214817-B1 | NITROGEN MACROCYCLE COMPLEXES WITH MANGANESE AND IRON | MONSANTO COMPANY | 2001-04-10 | — | — | US | disclosed |
| WO-2001019823-A2 | SUBSTITUTED PYRIDINO PENTAAZAMACROCYLE COMPLEXES HAVING SUPEROXIDE DISMUTASE ACTIVITY | MONSANTO COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110722-A1 | Modified hyaluronic acid polymers | CD44, HAO2, HAO1 | ERN1 4463/4885TERT 2716/4885CCR1 3338/4885 |
| US-20120301403-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | SOD1, SOD3, CAT | ERN1 1105/4885TERT 593/4885CCR1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.